Adriamycin
Authors: ROBERT S. BENJAMIN
Journal: Annals of Internal Medicine (1974)

Comments and Corrections1 September 1974AdriamycinROBERT S. BENJAMIN, M.D., PETER H. WIERNIK, M.D., NICHOLAS R. BACHUR, M.D., PH.D.ROBERT S. BENJAMIN, M.D.Search for more papers by this author, PETER H. WIERNIK, M.D.Search for more papers by this author, NICHOLAS R. BACHUR, M.D., PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-81-3-414 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the recent review of Blum and Carter on adriamycin (1). We are concerned, however, lest the authors' apparent misinterpretation of our data confuse your readers, and therefore, we should like to clarify certain issues, as well as to update the references to our work.With regard first to biochemistry, in 1972 we were unable to demonstrate the presence of a reductase for adriamycin, but we have subsequently identified such a reaction and have isolated adriamycinol as a major metabolite of adriamycin in human urine (2, 3), bile (4), and plasma (3).With regard...References1. BLUMCARTER RS: Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259, 1974 LinkGoogle Scholar2. TAKANASHIBACHUR SN: New adriamycin (A) and daunorubicin (D) metabolites in human urine (abstract). Proc Am Assoc Cancer Res 15:76, 1974 Google Scholar3. BENJAMINRIGGSSERPICK RCA: Human metabolism of adriamycin (A) (abstract). Ibid. Google Scholar4. BENJAMINRIGGSSERPICK RCA: Biliary excretion of adriamycin (A) in man (abstract). Clin Res 22:483A, 1974 Google Scholar5. BENJAMINRIGGSBACHUR RCN: The pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592-600, 1973 CrossrefMedlineGoogle Scholar6. BENJAMINWIERNIKBACHUR RPN: Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33:19-27, 1974 CrossrefMedlineGoogle Scholar7. BACHUREGORINHILDEBRAND NMR: Human biliary metabolites of adriamycin (A) and daunorubicin (D) (abstract). Proc Am Assoc Cancer Res 14:14, 1973 Google Scholar8. BENJAMINWIERNIKBACHUR RPN: Adriamycin (AMN) —efficacy, safety, and pharmacologic basis of a single dosage schedule (ASCO abstract 35). Cancer Chemother Rep 57:98, 1973 Google Scholar9. KENISMICHEL YJ: Preliminary results of a clinical trial with intermittent doses of adriamycin in lung cancer, in International Symposium on Adriamycin, edited by CARTER SK, DIMARCO A, GHIONE M, et al. New York, Springer-Verlag New York, Inc., 1972, pp. 161-164 CrossrefGoogle Scholar10. KENISMICHELRIMOLDI YJR: Results of a clinical trial with intermittent doses of adriamycin in lung cancer. Eur J. Cancer 8:485-489, 1972 CrossrefMedlineGoogle Scholar11. FREILUCEMIDDLEMAN EJE: Clinical trials of adriamycin. See Reference 9, pp. 153-160 Google Scholar12. BONADONNAMONFARDINIDELENA GSM: Clinical trials with adriamycin. Results of a three year study. See Reference 9, pp. 139-152 Google Scholar13. GOTTLIEBBONNETHOOGSTRATEN JJB: Superiority of adriamycin over oral nitrosoureas in patients with breast cancer (ASCO abstract 37). Cancer Chemother Rep 57:98, 1973 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ROBERT S. BENJAMIN, M.D.; PETER H. WIERNIK, M.D.; NICHOLAS R. BACHUR, M.D., PH.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022 1 September 1974Volume 81, Issue 3Page: 414-415KeywordsBileBiochemistryBlood plasmaMetabolitesUrine ePublished: 1 December 2008 Issue Published: 1 September 1974 PDF downloadLoading ...